Advanced searches left 3/3

Car T Cell Therapy - DOAJ

Summarized by Plex Scholar
Last Updated: 10 August 2022

* If you want to update the article please login/register

CD19+ lineage chimerism, an early biomarker after anti-CD19 CAR-T cell therapy in patients previously receiving a hematopoietic stem cell transplantation

A chimeric antigen receptor expressed on T cells in a treatment of relapsed and refractory B-cell acute lymphoblastic leukemia has resulted in a breakthrough in the diagnosis and treatment of relapsed and refractory B-cell acute lymphoblastic leukemia. After infusion, the success of anti-CD19 CAR-T is monitored by bone marrow-positive minimal residual disease and the absence of peripheral CD19+ B lymphocytes. We recommend that continuous lineage chimerism testing be performed in patients with anti-CD19 CAR-T cells after HSCT and complete remission because it promotes early treatment intervention.

Source link: https://doi.org/10.3389/fimmu.2022.960412


Humoral Responses to Repetitive Doses of COVID-19 mRNA Vaccines in Patients with CAR-T-Cell Therapy

COVID-19 vaccines were evaluated by IgG antibody tests against SARS-CoV-2 spike protein, a COVID-19 vaccine. CAR-T-cells led to two to four vaccine doses; group : CAR-T-cells first developed before CAR-T-cells; group : Two vaccine doses before CAR-T-cells were followed by two to four vaccine doses; group : CAR-T-cells was followed by two to four vaccine doses; group : Two vaccine doses before CAR-T-cells were administered, followed by doses 3 or 4. Result : After a second dose, 9/23 after a third dose, and 3/3 patients after a fourth dose, 7/30 patients had positive antibody tests after a second dose, and 3/3 patients after a fourth dose. After a second dose, 3/8 patients after a third dose, and 3/4 patients after a fourth dose, 6/14 patients had a positive antibody test, and 6/14 patients after a fourth dose.

Source link: https://doi.org/10.3390/cancers14143527


Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany

The aim of this survey was to determine the incremental cost of chimeric antigen receptor T-cell therapy in adult patients with relapsed or refractory diffuse large B-cell lymphoma from the German third-party payer perspective. Estimation of the third-line population based on outcome results from peer-reviewed journals, a top-down strategy based on population forecasts, and age-standardized incidences. The cost of treating second-line DLBCL patients was estimated in the scenario study. According to the population 2021-2026, 788-867, and 1,068-1,177 adult third-line r/r DLBCL patients were estimated. Year 5,394,514; u20ac39,416,514; year 0 to u20ac202,105,033,001; u20ac165,763,001 in year 5. This budget impact analysis revealed a substantial yet fair financial burden associated with CAR T-cell therapy for a small number of patients requiring individual care. This report, as well as cost analysis in personalized medicine, raises the risks and future needs in data exchange.

Source link: https://doi.org/10.1097/HS9.0000000000000736


The role of neurologists in the era of cancer immunotherapy: Focus on CAR T-cell therapy and immune checkpoint inhibitors

Cancer immunotherapy is a new anticancer treatment that depends specifically on the immune system, triggering its release of cancer cells in the hopes of increasing the body's natural ability to fight cancer. Among many treatments and research, chimeric antigen receptors T-cell therapy and immune checkpoint inhibitors have consistently demonstrated their effectiveness. Embegliopathy occurs in up to 77% of patients who received CAR T-cell therapy and often presents with encephalopathy characterized by a predominant frontal lobe dysfunction. Following ICI therapy, unrestrained T-cells may result in central and peripheral neurological disorders caused by antigen-directed autoimmunity, according to the other hand. Notably, physiological and clinical similarities have been highlighted between neurotoxicity related to CAR T-cell therapy and neurological manifestations of cytokine storms, as well as a subgroup of ICI-related neurological adverse events and paraneoplastic neurological syndromes.

Source link: https://doi.org/10.3389/fneur.2022.936141


Clinical Investigations of CAR-T Cell Therapy for Solid Tumors

Cell therapy is a favored targeted immunotherapy with a strong ability to treat solid tumors in the new era of cancer therapy. Genetically engineered cell products and non-genetically engineered cell products are two examples of cell therapy solutions offered by Cell therapy firms. Several new cell therapies, including chimeric antigen receptor -T cell therapies, have been listed as novel cancer treatment options. Numerous clinical trials on cell therapy, in the form of cell therapy alone or in combination with other drugs in solid tumors, have been published or ongoing.

Source link: https://doi.org/10.3389/fimmu.2022.896685

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions